{"entity":{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","aka":[],"tldr":"Surgeon-scientist whose personalised mRNA vaccine trial showed pancreatic cancer can provoke lasting T-cell immunity.","summary":"Vinod Balachandran led the phase 1 trial of the individualised mRNA neoantigen vaccine autogene cevumeran after pancreatic cancer surgery, showing that half of patients mounted durable neoantigen-specific T cells and that responders had markedly longer recurrence-free survival. His earlier Nature paper showed long-term pancreatic cancer survivors have high-quality neoantigens. He leads the phase 2 IMCODE003 trial.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Vinod_P._Balachandran","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balachandran%20VP%5BAuthor%5D%20pancreatic%20vaccine"}],"tags":["pancreatic","vaccine","immunotherapy"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":["autogene-cevumeran"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Surgical Oncologist and Member, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Pancreatic cancer","Neoantigen vaccines","Tumour immunology","Hepatopancreatobiliary surgery"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Balachandran%20VP%5BAuthor%5D%20pancreatic%20vaccine"}],"papers":[{"title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","journal":"Nature","year":2023,"doi":"10.1038/s41586-023-06063-w"},{"title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","journal":"Nature","year":2017,"doi":"10.1038/nature24462"},{"title":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","journal":"Nature","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Personalized%20RNA%20neoantigen%20vaccines%20stimulate%20T%20cells%20in%20pancreatic%20cancer%20Rojas%20Nature%202023"}],"orcid":"0000-0002-2956-223X"},"route":"/people/vinod-balachandran/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"paper":[{"id":"paper-park-hrd-pancreatic-platinum-ccr-2020","kind":"paper","name":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","route":"/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/"},{"id":"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","kind":"paper","name":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","route":"/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/"},{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/"},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"trial":[{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/"}]}}